Key Points
- Insider sale: Director Derek Maetzold sold 650 shares on March 18 at an average price of $25.39 for proceeds of $16,503.50, reducing his stake by 2.94% to 21,479 shares (≈$545,352).
- Recent results and stock metrics: Castle reported an EPS of ($0.08) vs. ($0.23) consensus and revenue of $81.88M, but remains unprofitable (net margin -7.02%, P/E -29.64); the stock trades near $25.20 with a market cap of ~$749M and a 52‑week range of $14.59–$44.28.
- Analyst and institutional backdrop: Analysts show a "Moderate Buy" consensus (8 Buys, 1 Hold, 1 Sell) with an average price target of $47.57, and institutional ownership is high (~92.6%) with large stakes held by Vanguard, RTW, Principal and others.
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 650 shares of Castle Biosciences stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $25.39, for a total transaction of $16,503.50. Following the sale, the insider owned 21,479 shares of the company's stock, valued at approximately $545,351.81. The trade was a 2.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Castle Biosciences Stock Performance
Shares of Castle Biosciences stock traded down $0.51 during trading on Friday, hitting $25.20. 29,233 shares of the company's stock were exchanged, compared to its average volume of 410,617. The stock has a market capitalization of $749.05 million, a price-to-earnings ratio of -29.64 and a beta of 1.09. The business has a 50-day simple moving average of $33.50 and a 200-day simple moving average of $31.69. Castle Biosciences, Inc. has a 52-week low of $14.59 and a 52-week high of $44.28. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.11 and a current ratio of 5.26.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.15. The company had revenue of $81.88 million for the quarter, compared to the consensus estimate of $81.19 million. Castle Biosciences had a negative return on equity of 0.89% and a negative net margin of 7.02%. On average, research analysts forecast that Castle Biosciences, Inc. will post 0.44 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on CSTL shares. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Castle Biosciences in a research note on Monday, December 29th. Robert W. Baird lifted their price objective on shares of Castle Biosciences from $41.00 to $44.00 and gave the company an "outperform" rating in a report on Friday, February 27th. Lake Street Capital raised their target price on Castle Biosciences from $35.00 to $52.00 and gave the company a "buy" rating in a research report on Monday, January 12th. KeyCorp restated an "overweight" rating and issued a $50.00 price target on shares of Castle Biosciences in a research note on Thursday, January 29th. Finally, BTIG Research upped their price target on Castle Biosciences from $38.00 to $50.00 and gave the stock a "buy" rating in a report on Friday, December 12th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $47.57.
Get Our Latest Stock Analysis on CSTL
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of CSTL. Vanguard Group Inc. increased its stake in Castle Biosciences by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 2,199,829 shares of the company's stock worth $85,573,000 after buying an additional 27,511 shares in the last quarter. RTW Investments LP purchased a new stake in shares of Castle Biosciences during the fourth quarter worth approximately $82,283,000. Principal Financial Group Inc. raised its stake in Castle Biosciences by 0.7% in the 4th quarter. Principal Financial Group Inc. now owns 1,807,644 shares of the company's stock valued at $70,317,000 after purchasing an additional 13,289 shares during the last quarter. Portolan Capital Management LLC lifted its holdings in Castle Biosciences by 1.7% in the 3rd quarter. Portolan Capital Management LLC now owns 1,515,111 shares of the company's stock valued at $34,499,000 after purchasing an additional 25,539 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Castle Biosciences by 7.0% during the third quarter. Dimensional Fund Advisors LP now owns 1,474,089 shares of the company's stock worth $33,564,000 after buying an additional 96,084 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.
Castle Biosciences Company Profile
(
Get Free Report)
Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.
The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
